春季角结膜炎严重程度与睑板腺功能障碍相关性的横断面研究

注册号:

Registration number:

ChiCTR2600125435 

最近更新日期:

Date of Last Refreshed on:

2026-05-27 09:25:54 

注册时间:

Date of Registration:

2026-05-27 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

春季角结膜炎严重程度与睑板腺功能障碍相关性的横断面研究

Public title:

A Cross-Sectional Study on the Association Between the Severity of Spring Keratoconjunctivitis and Meibomian Gland Dysfunction

注册题目简写:

English Acronym:

研究课题的正式科学名称:

春季角结膜炎严重程度与睑板腺功能障碍相关性的横断面研究

Scientific title:

A Cross-Sectional Study on the Association Between the Severity of Spring Keratoconjunctivitis and Meibomian Gland Dysfunction

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

严佳怡 

研究负责人:

陈蔚 

Applicant:

Yan Jiayi 

Study leader:

Wei Chen 

申请注册联系人电话:

Applicant telephone:

+86 18646372888

研究负责人电话:

Study leader's
telephone:

+86 577 8839 6800

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1241934091@qq.com

研究负责人电子邮件:

Study leader's E-mail:

chenweimd@wmu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

浙江省温州市鹿城区学院西路270号

研究负责人通讯地址:

浙江省温州市鹿城区学院西路270号

Applicant address:

270 Xiayue West Road, Lucheng District, Wenzhou City, Zhejiang

Study leader's address:

270 Xiayue West Road, Lucheng District, Wenzhou City, Zhejiang

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

温州医科大学附属眼视光医院

Applicant's institution:

Eye Hospital, Wenzhou Medical University

研究负责人所在单位:

温州医科大学附属眼视光医院

Affiliation of the Leader:

Eye Hospital, Wenzhou Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

温医大眼视光伦审2026研第121号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

温州医科大学附属眼视光医院伦理委员会

Name of the ethic committee:

Ethics committee of Eye Hospital of Wenzhou Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2026-05-19 00:00:00

伦理委员会联系人:

谷佩秋

Contact Name of the ethic committee:

Gu PeiQiu

伦理委员会联系地址:

浙江省温州市鹿城区学院西路270号

Contact Address of the ethic committee:

270 Xiayue West Road, Lucheng District, Wenzhou City, Zhejiang

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 577 88075582

伦理委员会联系人邮箱:

Contact email of the ethic committee:

gupeiqiu@126.com

研究实施负责(组长)单位:

温州医科大学附属眼视光医院

Primary sponsor:

Eye Hospital, Wenzhou Medical University

研究实施负责(组长)单位地址:

浙江省温州市鹿城区学院西路270号

Primary sponsor's address:

270 Xiayue West Road, Lucheng District, Wenzhou City, Zhejiang

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江省

市(区县):

Country:

China

Province:

Zhejiang

City:

单位(医院):

温州医科大学附属眼视光医院

具体地址:

浙江省温州市鹿城区学院西路270号

Institution
hospital:

Eye Hospital, Wenzhou Medical University

Address:

270 Xiayue West Road, Lucheng District, Wenzhou City, Zhejiang

经费或物资来源:

浙江省科技计划项目

Source(s) of funding:

Zhejiang Provincial Science and Technology Program Projects

研究疾病:

春季角结膜炎  

Target disease:

vernal keratoconjunctivitis

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

病例对照研究 

Study design:

Case-Control study 

研究目的:

探究儿童春季角结膜炎(VKC)严重程度与睑板腺功能障碍(MGD)之间的相关性,明确不同严重程度VKC患儿睑板腺结构与功能的差异,为临床早期干预提供依据。  

Objectives of Study:

To investigate the association between the severity of viral keratoconjunctivitis (VKC) in children and meibomian gland dysfunction (MGD), and to clarify the differences in the structure and function of the meibomian glands among children with VKC of varying severity, thereby providing a basis for early clinical intervention.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.眼部外伤史或手术史;
2.除春季角膜炎外的其他活动性眼部感染;
3.近3个月内使用过影响睑板腺功能的局部/全身药物(如阿奇霉素、强力霉素、异维A酸、局部糖皮质激素、免疫抑制剂、抗过敏药);
4.明确感染性睑缘炎;
5.活动性严重角膜溃疡未愈合;
6.佩戴角膜接触镜(包括软性、硬性及角膜塑形镜);
7.Bonini 4级(盾形溃疡)或5级(瘢痕期)患儿;

Exclusion criteria:

1.History of eye trauma or surgery;
2.Active eye infections other than vernal keratitis;
3.Use of topical or systemic medications that affect meibomian gland function within the past 3 months (e.g., azithromycin, doxycycline, isotretinoin, topical corticosteroids, immunosuppressants, antiallergic medications);
4.Confirmed infectious blepharitis;
5.Active, severe corneal ulcer that has not healed;
6.Wearing contact lenses (including soft, hard, and orthokeratology lenses);
7.Children with Bonini stage 4 (shield-shaped ulcer) or stage 5 (scarring stage);

研究实施时间:

Study execute time:

From 2026-04-16 00:00:00 To 2027-04-16 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-06-04 00:00:00 To 2026-12-08 00:00:00

干预措施:

Interventions:

组别:

重度 VKC

样本量:

35

Group:

Severe VKC

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

轻度VKC

样本量:

35

Group:

Mild VKC

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

中度VKC

样本量:

35

Group:

Moderate VKC

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

健康组

样本量:

35

Group:

Health Group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江省 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

温州医科大学附属眼视光医院 

单位级别:

三级甲等 

Institution
hospital:

Eye Hospital, Wenzhou Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

结膜乳头

指标类型:

次要指标

Outcome:

Conjunctival papillae

Type:

Secondary indicator

测量时间点:

就诊时

测量方法:

裂隙灯

Measure time point of outcome:

When visiting the clinic

Measure method:

Slit lamp

指标中文名:

睑板腺堵塞程度

指标类型:

次要指标

Outcome:

Degree of meibomian gland obstruction

Type:

Secondary indicator

测量时间点:

就诊时

测量方法:

裂隙灯

Measure time point of outcome:

When visiting the clinic

Measure method:

Slit lamp

指标中文名:

睑板腺分泌物

指标类型:

次要指标

Outcome:

Meibomian gland secretions

Type:

Secondary indicator

测量时间点:

就诊时

测量方法:

裂隙灯

Measure time point of outcome:

When visiting the clinic

Measure method:

Slit lamp

指标中文名:

睑缘充血

指标类型:

次要指标

Outcome:

Erythema of the eyelid margin

Type:

Secondary indicator

测量时间点:

就诊时

测量方法:

裂隙灯

Measure time point of outcome:

When visiting the clinic

Measure method:

Slit lamp

指标中文名:

FBUT

指标类型:

次要指标

Outcome:

FBUT

Type:

Secondary indicator

测量时间点:

就诊时

测量方法:

裂隙灯

Measure time point of outcome:

When visiting the clinic

Measure method:

Slit lamp

指标中文名:

结膜充血

指标类型:

次要指标

Outcome:

Conjunctival hyperemia

Type:

Secondary indicator

测量时间点:

就诊时

测量方法:

裂隙灯

Measure time point of outcome:

When visiting the clinic

Measure method:

Slit lamp

指标中文名:

睑板腺面积

指标类型:

主要指标

Outcome:

Area of the meibomian glands

Type:

Primary indicator

测量时间点:

就诊时

测量方法:

Keratograph 5M

Measure time point of outcome:

When visiting the clinic

Measure method:

Keratograph 5M

指标中文名:

角膜染色

指标类型:

次要指标

Outcome:

Corneal staining

Type:

Secondary indicator

测量时间点:

就诊时

测量方法:

裂隙灯

Measure time point of outcome:

When visiting the clinic

Measure method:

Slit lamp

指标中文名:

Horner- Trantas结节

指标类型:

次要指标

Outcome:

Horner- Trantas

Type:

Secondary indicator

测量时间点:

就诊时

测量方法:

裂隙灯

Measure time point of outcome:

When visiting the clinic

Measure method:

Slit lamp

指标中文名:

结膜水肿

指标类型:

次要指标

Outcome:

Conjunctival edema

Type:

Secondary indicator

测量时间点:

就诊时

测量方法:

裂隙灯

Measure time point of outcome:

When visiting the clinic

Measure method:

Slit lamp

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 8 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

CRF+Excel

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form,CRF+Excel

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2026-05-27 09:25:45